Former Biopure Corp. head of regulatory affairs Howard Richman agreed to pay a $150,000 penalty to settle allegations that he misled investors about the Cambridge biotechnology company's efforts to obtain approval for its synthetic blood product, Hemopure.
Richman will also be permanently barred from serving as an officer or director of any public company under the final judgment entered in US District Court in Boston. The settlement resolves a 2005 lawsuit by the Securities and Exchange Commission. The SEC previously settled with three other former Biopure executives.
Source
No comments:
Post a Comment